Cargando…

Treatment of disseminated granuloma annulare with fumaric acid esters

BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreuter, Alexander, Gambichler, Thilo, Altmeyer, Peter, Brockmeyer, Norbert H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101386/
https://www.ncbi.nlm.nih.gov/pubmed/11914154
_version_ 1782120201382264832
author Kreuter, Alexander
Gambichler, Thilo
Altmeyer, Peter
Brockmeyer, Norbert H
author_facet Kreuter, Alexander
Gambichler, Thilo
Altmeyer, Peter
Brockmeyer, Norbert H
author_sort Kreuter, Alexander
collection PubMed
description BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE). CASE PRESENTATION: A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. With the exception of temporary lymphopenia, no adverse effects were observed. The patient remained in remission during a six-month follow up period. CONCLUSIONS: Our observation has demonstrated that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA.
format Text
id pubmed-101386
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1013862002-04-11 Treatment of disseminated granuloma annulare with fumaric acid esters Kreuter, Alexander Gambichler, Thilo Altmeyer, Peter Brockmeyer, Norbert H BMC Dermatol Case Report BACKGROUND: Granuloma annulare is a granulomatous disease of unknown etiology. Various therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids, several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was treated with fumaric acid esters (FAE). CASE PRESENTATION: A 40-year old Caucasian woman presented with a 25-year history of recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She was treated with FAE in tablet form using two formulations differing in strength (low strength tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt). After three-month therapy, an almost complete clearance of skin lesions was achieved. With the exception of temporary lymphopenia, no adverse effects were observed. The patient remained in remission during a six-month follow up period. CONCLUSIONS: Our observation has demonstrated that FAE is a potentially beneficial therapeutic option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore the efficacy, optimal dosage, and safety of FAE in the management of DGA. BioMed Central 2002-03-19 /pmc/articles/PMC101386/ /pubmed/11914154 Text en Copyright © 2002 Kreuter et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Case Report
Kreuter, Alexander
Gambichler, Thilo
Altmeyer, Peter
Brockmeyer, Norbert H
Treatment of disseminated granuloma annulare with fumaric acid esters
title Treatment of disseminated granuloma annulare with fumaric acid esters
title_full Treatment of disseminated granuloma annulare with fumaric acid esters
title_fullStr Treatment of disseminated granuloma annulare with fumaric acid esters
title_full_unstemmed Treatment of disseminated granuloma annulare with fumaric acid esters
title_short Treatment of disseminated granuloma annulare with fumaric acid esters
title_sort treatment of disseminated granuloma annulare with fumaric acid esters
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101386/
https://www.ncbi.nlm.nih.gov/pubmed/11914154
work_keys_str_mv AT kreuteralexander treatmentofdisseminatedgranulomaannularewithfumaricacidesters
AT gambichlerthilo treatmentofdisseminatedgranulomaannularewithfumaricacidesters
AT altmeyerpeter treatmentofdisseminatedgranulomaannularewithfumaricacidesters
AT brockmeyernorberth treatmentofdisseminatedgranulomaannularewithfumaricacidesters